Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective intergroup trial of p53 predictive value in neoadjuvant chemotherapy for locally advanced or large operable breast cancer
ISRCTN58579496Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Apr 2001
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of epirubicin, fluorouracil, cyclophosphamide, docetaxel and filgrastim in breast cancer and inflammatory breast cancer (IBC) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-free survival. Started Apr 2001; status: completed.
02
Drugs
epirubicinfluorouracilcyclophosphamidedocetaxelfilgrastim
03
Conditions
breast cancerinflammatory breast cancer (IBC)
Beyond the preview
Go deeper on ISRCTN58579496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN58579496.